Alzheimer's disease: Biomarkers in the genome, blood, and cerebrospinal fluid

Frontiers in Neurology

Volumn 8, Issue MAR, 2017, Pages

  Huynh, Rose Ann ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Alzheimer's disease; Blood derived biomarkers; Early detection; Genetic biomarkers; Longitudinal studies; Neurochemical biomarkers

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BETA SECRETASE 1; BIOLOGICAL MARKER; CELL PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; CHITINASE 3 LIKE PROTEIN 1; LIPID; MICRORNA; NEUROGRANIN; PLASMA PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ; VISININ LIKE PROTEIN 1;

ALLELE; ALZHEIMER DISEASE; APOE EPSILON4 GENE; AUTOPSY; BEHAVIOR CHANGE; CEREBROSPINAL FLUID EXAMINATION; DISEASE COURSE; DISEASE MARKER; GENETIC MARKER; GENETIC RISK; GENETIC SCREENING; GENOME; HUMAN; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SCORING SYSTEM; SENILE PLAQUE; THOUGHT DISORDER;

EID: 85016136033     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2017.00102     Document Type: Review

References (121)

1. Alzheimer's Association. Alzheimer's Disease Facts and Figures. (2013). Available from: https://www.alz.org/downloads/facts_figures_2013.pdf
2. Alzheimer's Disease Education and Referral (ADEAR) Center. Alzheimer's Disease Fact Sheet. NIH Publication No. 11-6423 (2011). Available from: https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet
3. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, et al. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol (2013) 260:640-50. doi:10.1007/s00415-012-6694-0
4. Murphy MP, Levine H III. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 19:311-23. doi:10.3233/JAD-2009-1221
5. Baird AL, Westwood S, Lovestone S. Blood-based proteomic biomarkers of Alzheimer's disease pathology. Front Neurol (2015) 6:236. doi:10.3389/fneur.2015.00236
6. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol (2014) 71:1379-85. doi:10.1001/jamaneurol.2014.2031
7. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging B-amyloid burden in aging and dementia. Neurology (2007) 68:1718-25. doi:10.1212/01.wnl.0000318046.06992.24
8. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 84:608-22. doi:10.1016/j.neuron.2014.10.038
9. Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimers Dement (2014) 10:S196-212. doi:10.1016/j.jalz.2014.04.015
10. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2011) 29:26-32. doi:10.1016/j.tibtech.2010.09.007
11. Onos KD, Sukoff Rizzo SJ, Howell GR, Sasner M. Toward more predictive genetic mouse models of Alzheimer's disease. Brain Res Bull (2016) 122:1-11. doi:10.1016/j.brainresbull.2015.12.003
12. Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z. Potential neuroimaging biomarkers of pathologic brain changes in mild cognitive impairment and Alzheimer's disease: a systematic review. BMC Geriatr (2016) 16:104. doi:10.1186/s12877-016-0281-7
13. Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer's disease biomarkers: correspondence between human studies and animal models. Neurobiol Dis (2013) 56:116-30. doi:10.1016/j.nbd.2013.04.010
14. Salvatore C, Cerasa A, Battista P, Gilardi MC, Quattrone A, Castiglioni I. Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer's disease: a machine learning approach. Front Neurosci (2015) 9:307. doi:10.3389/fnins.2015.00307
15. Panegyres PK, Chen H-Y. Differences between early and late onset Alzheimer's disease. Am J Neurodegener Dis (2013) 2:300-6. doi:10.1176/appi.neuropsych.12100240
16. Foo J, Liu J, Tan E. Whole-genome and whole-exome sequencing in neurological diseases. Nat Rev Neurol (2012) 8:508-17. doi:10.1038/nrneurol.2012.148
17. Beck J, Pittman A, Adamson G, Campbell T, Kenny J, Houlden H, et al. Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiol Aging (2014) 35:261-5. doi:10.1016/j.neurobiolaging.2013.07.017
18. Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard AC, et al. Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. Eur J Hum Genet (2015) 24:1-7. doi:10.1038/ejhg.2015.173
19. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med (2015) 18:421-30. doi:10.1038/gim.2015.117
20. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement (2015) 11:332-84. doi:10.1016/j.jalz.2015.02.003
21. Loy CT, Schofield PR, Turner AM, Kwok JB. Review: genetics of dementia. Lancet (2014) 383:828-40. doi:10.1016/S0140-6736(13)60630-3
22. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A. Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature (2013) 500:45-50. doi:10.1038/nature12415
23. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med (2011) 49:375-83. doi:10.1515/CCLM.2011.088
24. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA (1997) 278:1349-56. doi:10.1001/jama.1997.03550160069041
25. Liu C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 9:106-18. doi:10.1038/nrneurol.2013.32
26. Saunders AM, Hulette C, Welsh-Bohmer KA, Schmechel DE, Crain B, Burke JR, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (1996) 348:90-3. doi:10.1016/S0140-6736(96)01251-2
27. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-e4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry (2011) 82:1149-56. doi:10.1136/jnnp.2010.231555
28. Vos SJ, Van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 80:1-9. doi:10.1212/WNL.0b013e318288690c
29. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 12:957-65. doi:10.1016/S1474-4422(13)70194-7
30. Corder E, Saunders A, Strittmatter D, Schmechel D, Gaskell P, Small G, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease on late onset families. Science (1993) 261:921-3. doi:10.1126/science.8346443
31. Gupta VB. Plasma apolipoprotein E and Alzheimer disease risk. Neurology (2011) 76:1091-8. doi:10.1212/WNL.0b013e318211c352
32. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 45:1452-8. doi:10.1038/ng.2802
33. Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry (2013) 18:1225-34. doi:10.1038/mp.2013.1
34. Tan MS, Yu JT, Tan L. Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. Trends Mol Med (2013) 19:594-603. doi:10.1016/j.molmed.2013.06.004
35. Calafate S, Flavin W, Verstreken P, Moechars D. Loss of Bin1 promotes the propagation of Tau pathology. Cell Rep (2016) 17:931-40. doi:10.1016/j.celrep.2016.09.063
36. Sottejeau Y, Bretteville A, Cantrelle FX, Malmanche N, Demiaute F, Mendes T, et al. Tau phosphorylation regulates the interaction between BIN1's SH3 domain and Tau's proline-rich domain. Acta Neuropathol Commun (2015) 3:58. doi:10.1186/s40478-015-0237-8
37. Belbin O, Carrasquillo MM, Crump M, Culley OJ, Hunter TA, Ma L, et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease. Hum Genet (2011) 129:273-82. doi:10.1007/s00439-010-0924-2
38. Seshadri S, Fitzpatrick A, Ikram M, DeStefano A, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci. JAMA (2010) 303:1832-40. doi:10.1001/jama.2010.574
39. Thomas RS, Henson A, Gerrish A, Jones L, Williams J, Kidd EJ. Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer's disease. BMC Neurosci (2016) 17:50. doi:10.1186/s12868-016-0288-1
40. Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J, et al. Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta. Neurosci Bull (2014) 30:162-8. doi:10.1007/s12264-013-1391-2
41. Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol (2014) 71:180-7. doi:10.1001/jamaneurol.2013.4560
42. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in alzheimer disease. Arch Gen Psychiatry (2010) 67:739-48. doi:10.1001/archgenpsychiatry.2010.78
43. Yu JT, Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol (2012) 45:314-26. doi:10.1007/s12035-012-8237-1
44. Weinstein G, Beiser AS, Preis SR, Courchesne P, Chouraki V, Levy D, et al. Blood-based biomarkers plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke. Alzheimers Dement (2016) 3:103-9. doi:10.1016/j.dadm.2016.06.005
45. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2013) 368:107-16. doi:10.1056/NEJMoa1211103
46. Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener (2015) 10:19. doi:10.1186/s13024-015-0016-9
47. Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci (2016) 17:201-7. doi:10.1038/nrn.2016.7
48. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med (2007) 4:e124. doi:10.1371/journal.pmed.0040124
49. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 476:214-9. doi:10.1038/nature10251
50. Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J, et al. Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol (2015) 72:15-24. doi:10.1001/jamaneurol.2014.3049
51. Adams HH, de Bruijn RFAG, Hofman A, Uitterlinden AG, van Duijn CM, Vernooij MW, et al. Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement (2015) 11:1277-85. doi:10.1016/j.jalz.2014.12.008
52. Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, et al. A 22-single nucleotide polymorphism Alzheimer risk score correlates with family history, onset age, and cerebrospinal fluid abeta. Alzheimers Dement (2015) 11:1452-60. doi:10.1016/j.jalz.2015.02.013
53. Morgen K, Ramirez A, Frölich L, Tost H, Plichta MM, Kölsch H, et al. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimers Dement (2014) 10:1-8. doi:10.1016/j.jalz.2013.11.001
54. Tapiola T, Alafuzoff I, Herukka S, Parkkinen L, Soininen H, Hartikainen P, et al. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 66:382-9. doi:10.1001/archneurol.2008.596
55. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 12:856-61. doi:10.1038/nm1438
56. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science (2002) 296:1991-5. doi:10.1126/science.1067122
57. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol (2003) 10:119-28. doi:10.1046/j.1468-1331.2003.00562.x
58. De Jong D, Jansen RW, Kremer BPH, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci (2006) 61:755-8. doi:10.1093/gerona/61.7.755
59. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2010) 56:248-53. doi:10.1373/clinchem.2009.130518
60. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 65:403-13. doi:10.1002/ana.21610
61. Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther (2009) 15:358-74. doi:10.1111/j.1755-5949.2009.00104.x
62. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid beta protein (ABeta) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at ABeta40 or ABeta42(43). J Biol Chem (1995) 270:7013-6. doi:10.1074/jbc.270.13.7013
63. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, et al. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One (2010) 5:e15725. doi:10.1371/journal.pone.0015725
64. Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther (2015) 7:30. doi:10.1186/s13195-015-0114-5
65. Karch CM, Jeng AT, Goate AM. Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem (2012) 287:42751-62. doi:10.1074/jbc.M112.380642
66. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2010) 15:138-45. doi:10.1038/mp.2008.84
67. Lloret A, Badia MC, Giraldo E, Ermak G, Alonso MD, Pallardó FV, et al. Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis (2011) 27:701-9. doi:10.3233/JAD-2011-110890
68. Braunewell KH, Szanto AJK. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+-sensor proteins. Cell Tissue Res (2009) 335:301-16. doi:10.1007/s00441-008-0716-3
69. Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol Dis (2001) 8:900-9. doi:10.1006/nbdi.2001.0432
70. Laterza O, Modur V, Crimmins DL, Olander J, Landt Y, Lee J, et al. Identification of novel brain biomarkers. Clin Chem (2006) 52:1713-21. doi:10.1373/clinchem.2006.070912
71. Tarawneh R, D'Angelo G, MacY E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 70:274-85. doi:10.1002/ana.22448
72. Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci (2014) 5:830-6. doi:10.1021/cn500101j
73. Vlassenko AG, Benzinger TLS, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta (2012) 1822:370-9. doi:10.1016/j.bbadis.2011.11.005
74. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 8:20. doi:10.1186/1750-1326-8-20
75. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 68:903-12. doi:10.1016/j.biopsych.2010.08.025
76. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev (2006) 15:194-202. doi:10.1158/1055-9965.EPI-05-0011
77. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies. PLoS One (2015) 10:e0135458. doi:10.1371/journal.pone.0135458
78. Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther (2015) 7:74. doi:10.1186/s13195-015-0161-y
79. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol (2015) 3:12-20. doi:10.1002/acn3.266
80. Chang JW, Schumacher E, Coulter PM II, Vinters HV, Watson JB. Dendritic translocation of RC3/neurogranin mRNA in normal aging, Alzheimer disease and fronto-temporal dementia. J Neuropathol Exp Neurol (1997) 56:1105-18. doi:10.1097/00005072-199710000-00004
81. Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol (2015) 72:1275-80. doi:10.1001/jamaneurol.2015.1867
82. De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E, et al. The cerebrospinal fluid neurogranin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer's disease. J Alzheimers Dis (2016) 53:1523-38. doi:10.3233/JAD-160227
83. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 6:89. doi:10.1186/s13195-014-0089-7
84. Demarin V, Zavoreo I, Kes VB, Šimundic AM. Biomarkers in Alzheimer's disease. Clin Chem Lab Med (2011) 49:773-8. doi:10.1515/CCLM.2011.139
85. Björkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One (2012) 7:e29868. doi:10.1371/journal.pone.0029868
86. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 13:1359-62. doi:10.1038/nm1653
87. Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement (2014) 10:799-807. doi:10.1016/j.jalz.2014.05.1749
88. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 38:515-31. doi:10.3233/JAD-130380
89. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 20:415-8. doi:10.1038/nm.3466
90. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol (2013) 14:R78. doi:10.1186/gb-2013-14-7-r78
91. Bhatnagar S, Chertkow H, Schipper HM, Yuan Z, Shetty V, Jenkins S, et al. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Front Mol Neurosci (2014) 7:2. doi:10.3389/fnmol.2014.00002
92. Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry (2014) 20:1-9. doi:10.1038/mp.2014.127
93. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 129:3042-50. doi:10.1093/brain/awl279
94. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 14:27-41. doi:10.1016/j.jalz.2008.05.420
95. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol (2012) 235:491-6. doi:10.1016/j.expneurol.2011.11.026
96. Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med (2011) 9:197-207. doi:10.1186/1479-5876-9-197
97. Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis (2014) 5:e1327. doi:10.1038/cddis.2014.270
98. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 12:357-67. doi:10.1016/S1474-4422(13)70044-9
99. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 5:655-60. doi:10.1016/S1474-4422(06)70501-4
100. Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement (2015) 11:249-57. doi:10.1016/j.jalz.2014.07.001
101. Lui J, Laws S, Li Q, Villemagne V, Ames D, Brown B, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis (2010) 20:1233-42. doi:10.3233/JAD-2010-090249
102. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement (2014) 10:53-61. doi:10.1016/j.jalz.2012.12.006
103. Fei M, Jianghua W, Rujuan M, Wei Z, Qian W. The relationship of plasma Abeta levels to dementia in aging individuals with mild cognitive impairment. J Neurol Sci (2011) 305:92-6. doi:10.1016/j.jns.2011.03.005
104. Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimer's Dement (2015) 1:48-60. doi:10.1016/j.dadm.2014.11.005
105. Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, et al. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2014) 19:519-26. doi:10.1038/mp.2013.40
106. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 6:228fs13. doi:10.1126/scitranslmed.3007941
107. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 69:181-92. doi:10.1002/ana.22248
108. Voyle N, Kim M, Proitsi P, Ashton NJ, Baird AL, Bazenet C, et al. Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry (2016) 6:e719. doi:10.1038/tp.2015.205
109. Chetelat G, La Joie R, Villain N, Perrotin A, De La Sayette V, Eustache F, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 2:356-65. doi:10.1016/j.nicl.2013.02.006
110. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology (2012) 78:709-19. doi:10.1212/WNL.0b013e318248e568
111. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol (2005) 62:758-65. doi:10.1001/archneur.62.5.758
112. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr (1997) 9(Suppl 1):173-8. doi:10.1017/S1041610297004870
113. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 6:226ra30. doi:10.1126/scitranslmed.3007901
114. Rodríguez-Rodríguez E, Sánchez-Juan P, Vázquez-Higuera JL, Mateo I, Pozueta A, Berciano J, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm (2013) 120:807-12. doi:10.1007/s00702-012-0920-x
115. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 69:1002-10. doi:10.1001/archneurol.2012.90
116. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 9:363-72. doi:10.1016/S1474-4422(10)70043-0
117. Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (2015) 1:1-8. doi:10.1016/j.dadm.2015.09.001
118. Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. Front Neurol (2015) 6:186. doi:10.3389/fneur.2015.00186
119. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 275:251-83. doi:10.1111/joim.12191
120. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:311-21. doi:10.1056/NEJMoa1312889
121. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:322-33. doi:10.1056/NEJMoa1304839